An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages

Episode Summary

Executive Summary: The episode features AltPep CEO Valerie Daggett discussing a structural theory of Alzheimer’s and related amyloid diseases: toxic alpha-sheet oligomers appear very early, drive downstream pathology, and can be detected and neutralized with synthetic peptides. AltPep’s SOBA diagnostic and SOBID therapeutic aim to enable earlier diagnosis, patient stratification, and disease modification beyond plaque-targeting approaches.

Main Topics: Why current Alzheimer’s therapies fall short (Priority: 5/5): Daggett argues that existing FDA-approved treatments target mature plaques too late in the disease process, after decades of silent progression, limiting clinical benefit. Alpha-sheet toxic oligomers as an early disease trigger (Priority: 5/5): AltPep’s core scientific thesis is that amyloidogenic proteins pass through a toxic alpha-sheet oligomer state that precedes plaque formation and helps initiate downstream pathology. Synthetic peptides as dual diagnostic and therapeutic tools (Priority: 5/5): The company uses synthetic alpha-sheet peptides because they bind the toxic oligomer structure selectively, enabling both blood-based detection and therapeutic neutralization. SOBA diagnostic development and use cases (Priority: 4/5): SOBA is a blood-based soluble oligomer binding assay designed for early detection, disease stratification, and monitoring treatment response across amyloid diseases. SOBID therapeutic mechanism and preclinical results (Priority: 5/5): SOBID is delivered intranasally, binds toxic oligomers, and promotes microglial clearance; animal studies showed prevention and reversal of Alzheimer’s-like effects in mice. Broader amyloid-disease platform and commercialization strategy (Priority: 4/5): AltPep sees the platform extending to Parkinson’s, transthyretin amyloidosis, type 2 diabetes, and other amyloid-related conditions, likely via pharma partnerships rather than building a full commercial sales operation.

Key Arguments: Alzheimer’s begins 10–20+ years before symptoms, so plaque-focused treatment is often too late to matter substantially. A structural target is superior to a sequence epitope because toxic oligomers share alpha-sheet structure across multiple amyloid diseases. Synthetic peptides can achieve highly selective nanomolar binding to toxic oligomers, making them suitable for both diagnosis and therapy. SOBA is linked directly to the mechanism of action, which is unusual and valuable for both patient selection and treatment monitoring. Preclinical studies suggest toxic oligomers are causative, since injecting purified alpha-sheet oligomers induced Alzheimer’s-like symptoms in wild-type mice. Intranasal SOBID reduced toxic oligomer burden and improved cognition/behavior in animal models, including later-stage models. The platform may work across many amyloid disorders because multiple amyloid systems appear to funnel through alpha-sheet structure. Commercially, the immediate goal is clinical validation; later-stage development and sales are likely better handled by partners.

Data Points: Estimated global disease burden: at least half a billion people - Daggett’s rough estimate of how many people worldwide may have some stage of Alzheimer’s disease Disease lead time before symptoms: 10 to 20 years, possibly 30 years - Time between onset of disease biology and clinical symptoms in Alzheimer’s Diagnostic timeline achieved in retrospective samples: 16 years ahead of time - Longest pre-symptomatic detection reported for SOBA in banked longitudinal samples Number of amyloid systems tested: 14 of 14 - Daggett says AltPep’s compounds have worked across all 14 amyloid systems studied so far Validation status of LDT: very close; expected in the next week or two - Timeline for finishing the lab-developed test paperwork and validation Clinical development timeline for therapeutic: next year - Planned entry into the clinic after IND-equivalent filing in Australia Animal study duration: 1 year of dosing - Longitudinal mouse study carried through to plaque stage to test SOBID effects Age of mice at endpoint: 15 months old - Endpoint age in the year-long dosing study Funding status: significant capital raised - Company has attracted investors despite a challenging early-stage biotech market

Pivotal Quotes: "the disease begins 10 to 20, some people even estimate 30 years prior to that, prior to the onset of symptoms" — Valerie Daggett: Explaining why plaque-targeting therapies have been limited and why early detection matters "We discovered this new structure, alpha sheet, and the peptides also have alpha sheet structure. And it's complementary and it's highly selective." — Valerie Daggett: Describing the scientific basis for AltPep’s diagnostic and therapeutic approach "our record so far is catching it 16 years ahead of time" — Valerie Daggett: Describing the earliest retrospective detection achieved by the SOBA assay

Implications: If validated clinically, AltPep’s platform could shift amyloid-disease care toward ultra-early screening, biomarker-guided treatment, and earlier intervention before irreversible neurodegeneration. It also suggests a broader multi-disease commercial path across amyloid disorders.